T. Rowe Price Associates’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $526K | Buy |
73,152
+18,766
| +35% | +$135K | ﹤0.01% | 2274 |
|
|
2025
Q1 | $326K | Buy |
54,386
+4,743
| +10% | +$28.4K | ﹤0.01% | 2425 |
|
|
2024
Q4 | $388K | Buy |
49,643
+5,486
| +12% | +$42.9K | ﹤0.01% | 2383 |
|
|
2024
Q3 | $477K | Buy |
44,157
+3,540
| +9% | +$38.2K | ﹤0.01% | 2264 |
|
|
2024
Q2 | $343K | Buy |
40,617
+5,406
| +15% | +$45.7K | ﹤0.01% | 2358 |
|
|
2024
Q1 | $237K | Buy |
35,211
+4,030
| +13% | +$27.1K | ﹤0.01% | 2537 |
|
|
2023
Q4 | $184K | Buy |
31,181
+1,526
| +5% | +$9.01K | ﹤0.01% | 2568 |
|
|
2023
Q3 | $290K | Buy |
29,655
+4,286
| +17% | +$41.9K | ﹤0.01% | 2342 |
|
|
2023
Q2 | $301K | Buy |
25,369
+1,868
| +8% | +$22.2K | ﹤0.01% | 2361 |
|
|
2023
Q1 | $254K | Buy |
23,501
+12,379
| +111% | +$134K | ﹤0.01% | 2425 |
|
|
2022
Q4 | $129K | Buy |
11,122
+1,018
| +10% | +$11.8K | ﹤0.01% | 2659 |
|
|
2022
Q3 | $151K | Buy |
+10,104
| New | +$151K | ﹤0.01% | 2624 |
|